Beck E A, Shainoff J R, Vogel A, Jackson D P
J Clin Invest. 1971 Sep;50(9):1874-84. doi: 10.1172/JCI106680.
The rate of clotting and the rate of development and degree of turbidity after addition of thrombin to plasma or purified fibrinogen from a patient with fibrinogen Baltimore was delayed when compared with normal, especially in the presence of low concentrations of thrombin. Optimal coagulation and development of translucent, rather than opaque, clots occurred at a lower pH with the abnormal fibrinogen than with normal. Development of turbidity during clotting of the abnormal plasma or fibrinogen was less than normal at each pH tested, but was maximal in both at approximately pH 6.4. The physical quality of clots formed from fibrinogen Baltimore was abnormal, as demonstrated by a decreased amplitude on thromboelastography. The morphologic appearance of fibrin strands formed from fibrinogen Baltimore by thrombin at pH 7.4 was abnormal when examined by phase contrast or electron microscopy, but those formed by thrombin at pH 6.4 or by thrombin and calcium chloride were similar to, though less compact, than normal fibrin. The periodicity of fibrin formed from fibrinogen Baltimore was similar to normal and was 231-233 A.A study of the release of the fibrinopeptides from the patient's fibrinogen and its chromatographic subfractions verified the existence of both a normally behaving and a defective form of fibrinogen in the patient's plasma. The defective form differed from normal in three functionally different ways: (a) the rate of release of fibrinopeptides A and AP was slower than normal; (b) no visible clot formation accompanied either partial or complete release of the fibrinopeptides from the defective form in 0.3 M NaCl at pH 7.4; and (c) the defective component possessed a high proportion of phosphorylated, relative to nonphosphorylated, fibrinopeptide A, while the coagulable component contained very little of the phosphorylated peptide (AP). The high phosphate content of the defective component did not appear to be the cause of the abnormality, but may be the result of an associated metabolic or genetic phenomenon.
与正常情况相比,向来自巴尔的摩纤维蛋白原血症患者的血浆或纯化纤维蛋白原中添加凝血酶后,凝血速率、浑浊度的发展速率和程度均延迟,尤其是在低浓度凝血酶存在的情况下。与正常纤维蛋白原相比,异常纤维蛋白原在较低pH值时发生最佳凝血并形成半透明而非不透明的凝块。在每个测试的pH值下,异常血浆或纤维蛋白原凝血过程中浑浊度的发展均低于正常情况,但在两者中,大约在pH 6.4时达到最大值。巴尔的摩纤维蛋白原形成的凝块的物理性质异常,血栓弹性图显示振幅降低。当通过相差显微镜或电子显微镜检查时,在pH 7.4下由巴尔的摩纤维蛋白原经凝血酶形成的纤维蛋白丝的形态外观异常,但在pH 6.4下由凝血酶形成的或由凝血酶和氯化钙形成的纤维蛋白丝与正常纤维蛋白相似,只是不太紧密。由巴尔的摩纤维蛋白原形成的纤维蛋白的周期性与正常情况相似,为231 - 233 Å。对患者纤维蛋白原及其色谱亚组分中纤维蛋白肽释放的研究证实,患者血浆中存在正常形式和缺陷形式的纤维蛋白原。缺陷形式在三个功能不同的方面与正常形式不同:(a) 纤维蛋白肽A和AP的释放速率比正常情况慢;(b) 在pH 7.4的0.3 M NaCl中,缺陷形式释放部分或全部纤维蛋白肽时均未出现可见的凝块形成;(c) 相对于未磷酸化的纤维蛋白肽A,缺陷组分中磷酸化的比例较高,而可凝固组分中含有的磷酸化肽(AP)很少。缺陷组分的高磷酸盐含量似乎不是异常的原因,而可能是相关代谢或遗传现象的结果。